DK1426049T3 - Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom - Google Patents

Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom

Info

Publication number
DK1426049T3
DK1426049T3 DK02026871T DK02026871T DK1426049T3 DK 1426049 T3 DK1426049 T3 DK 1426049T3 DK 02026871 T DK02026871 T DK 02026871T DK 02026871 T DK02026871 T DK 02026871T DK 1426049 T3 DK1426049 T3 DK 1426049T3
Authority
DK
Denmark
Prior art keywords
rotigotine
disease
treat parkinson
iontophoretic administration
composition
Prior art date
Application number
DK02026871T
Other languages
English (en)
Inventor
Hans-Michael Dr Wolff
Johanna Aaltje Bouwstra
Gai Ling Li
Akhmad Kharis Nugroho
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32309357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1426049(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Application granted granted Critical
Publication of DK1426049T3 publication Critical patent/DK1426049T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
DK02026871T 2002-12-02 2002-12-02 Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom DK1426049T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026871A EP1426049B1 (en) 2002-12-02 2002-12-02 Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease

Publications (1)

Publication Number Publication Date
DK1426049T3 true DK1426049T3 (da) 2005-08-22

Family

ID=32309357

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02026871T DK1426049T3 (da) 2002-12-02 2002-12-02 Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DK03785652T DK1567146T3 (da) 2002-12-02 2003-11-21 Iontophoretisk levering af rotigotin til behandlingen af Parkinsons sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03785652T DK1567146T3 (da) 2002-12-02 2003-11-21 Iontophoretisk levering af rotigotin til behandlingen af Parkinsons sygdom

Country Status (24)

Country Link
US (1) US7632859B2 (da)
EP (2) EP1426049B1 (da)
JP (1) JP2006514937A (da)
KR (1) KR101168431B1 (da)
CN (1) CN100333723C (da)
AT (2) ATE295726T1 (da)
AU (1) AU2003294718B2 (da)
BR (1) BR0316947A (da)
CA (1) CA2505040C (da)
CY (1) CY1106256T1 (da)
DE (2) DE60204229T2 (da)
DK (2) DK1426049T3 (da)
ES (2) ES2239196T3 (da)
HK (2) HK1065706A1 (da)
IL (1) IL168387A (da)
MX (1) MXPA05005462A (da)
NO (1) NO335491B1 (da)
NZ (1) NZ540190A (da)
PL (1) PL219696B1 (da)
PT (2) PT1426049E (da)
RU (2) RU2339372C2 (da)
SI (2) SI1426049T1 (da)
WO (1) WO2004050083A1 (da)
ZA (1) ZA200503750B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
EA017836B1 (ru) 2007-11-28 2013-03-29 ЮСиБи ФАРМА ГМБХ Новая полиморфная форма ротиготина и способ ее получения
DE102008010223A1 (de) 2008-02-20 2009-08-27 Wash Tec Holding Gmbh Reinigungsvorrichtung
DE202008002377U1 (de) 2008-02-20 2009-06-25 Washtec Holding Gmbh Reinigungsvorrichtung
EP2281559A1 (en) * 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
RS57457B1 (sr) 2009-12-22 2018-09-28 Ucb Biopharma Sprl Polivinilpirolidon za stabilizaciju čvrste disperzije nekristalnog oblika rotigotina
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
EP3145502B1 (en) 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermal delivery system containing rotigotine
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
EP3489227B1 (en) * 2016-07-21 2020-10-21 Shandong Luye Pharmaceutical Co., Ltd. Rotigotine behenate, and manufacturing method and application thereof

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108991A (en) * 1975-06-19 1992-04-28 Whitby Research, Inc. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4996226A (en) * 1984-08-13 1991-02-26 Whitby Research, Inc. Method and compositions for treatment of parkinsonism syndrome in mammels
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
WO1987004594A1 (en) * 1986-01-31 1987-08-13 Nelson Research And Development Company Compositions comprising 1-substituted azacycloalkanes and their uses
US4801586A (en) * 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5142044A (en) * 1986-04-23 1992-08-25 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4917896A (en) * 1986-08-15 1990-04-17 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5073544A (en) * 1986-08-15 1991-12-17 Whitby, Inc. Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes
US4808414A (en) * 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
US5118845A (en) * 1986-09-29 1992-06-02 Whitby Research, Inc. Penetration enhancer for transdermal delivery of systemic agents
US5273757A (en) * 1987-09-01 1993-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Apparatus for the delivery of substances, processes for the production thereof and use thereof
US5071645A (en) * 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
DE3868866D1 (de) * 1987-11-20 1992-04-09 Erba Carlo Spa Ergolinderivate mit antiparkinsonwirkung.
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5472946A (en) 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
DE3827561C1 (da) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5234945A (en) * 1989-05-09 1993-08-10 Whitby Research, Inc. Method of producing body weight and food intake using a dopamine D2 receptor agonist
US5252335A (en) * 1989-07-12 1993-10-12 Cygnus Therapeutic Systems Transdermal administration of lisuride
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
US5271940A (en) * 1989-09-14 1993-12-21 Cygnus Therapeutic Systems Transdermal delivery device having delayed onset
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5246997A (en) * 1990-02-21 1993-09-21 Dow Corning Corporation Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate
US5147916A (en) * 1990-02-21 1992-09-15 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive composition and related methods and articles
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US6086905A (en) * 1991-03-21 2000-07-11 Peck; James V. Topical compositions useful as skin penetration barriers
US5234690A (en) * 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5273755A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5273756A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5225198A (en) * 1991-08-27 1993-07-06 Cygnus Therapeutic Systems Transdermal administration of short or intermediate half-life benzodiazepines
JPH06510290A (ja) * 1991-08-27 1994-11-17 シグナス，インコーポレイテッド プラゾシンを投与するための経皮処方物
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
DE4301781C2 (de) * 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
US5804214A (en) * 1993-07-08 1998-09-08 Cygnus, Inc. Monolithic matrix transdermal delivery system for delivering ketorolac tromethamine
US5382596A (en) * 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
EP0643981B1 (en) * 1993-09-22 2002-01-09 Hisamitsu Pharmaceutical Co., Inc. A matrix for iontophoreses
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5677346A (en) * 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US5532278A (en) * 1995-01-31 1996-07-02 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
PL181582B1 (pl) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US6316022B1 (en) * 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US6063398A (en) * 1995-09-20 2000-05-16 L'oreal Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6221627B1 (en) * 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
US5879701A (en) * 1997-02-28 1999-03-09 Cygnus, Inc. Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents
US6242572B1 (en) * 1997-05-13 2001-06-05 Smithkline Beecham Corporation Human G protein coupled lysophosphatidic acid receptor
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
WO1999058190A1 (en) * 1998-05-13 1999-11-18 Cygnus, Inc. Collection assemblies for transdermal sampling system
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
JP2002524178A (ja) * 1998-09-17 2002-08-06 シグナス， インコーポレイテッド ゲル／センサアセンブリ用のプレス装置
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
AU5325000A (en) * 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
RU2266735C2 (ru) * 1999-11-29 2005-12-27 Лтс Ломанн Терапи-Системе Аг Трансдермальные терапевтические системы с повышенной стабильностью и способ их получения
US20020110585A1 (en) * 1999-11-30 2002-08-15 Godbey Kristin J. Patch therapeutic agent delivery device having texturized backing
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
EP1534235B1 (en) * 2002-06-25 2016-07-27 Acrux DDS Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
CA2503381A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US20050032873A1 (en) * 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss

Also Published As

Publication number Publication date
SI1567146T1 (sl) 2007-02-28
EP1567146A1 (en) 2005-08-31
RU2005114749A (ru) 2006-01-20
PL377575A1 (pl) 2006-02-06
EP1567146B1 (en) 2006-10-18
EP1426049A1 (en) 2004-06-09
RU2008121750A (ru) 2009-12-20
DE60309203D1 (de) 2006-11-30
AU2003294718A1 (en) 2004-06-23
AU2003294718B2 (en) 2008-07-31
NO335491B1 (no) 2014-12-22
KR101168431B1 (ko) 2012-07-25
SI1426049T1 (en) 2005-08-31
JP2006514937A (ja) 2006-05-18
EP1426049B1 (en) 2005-05-18
HK1079108A1 (en) 2006-03-31
ES2239196T3 (es) 2005-09-16
RU2478383C2 (ru) 2013-04-10
IL168387A (en) 2009-05-04
CN1720041A (zh) 2006-01-11
ATE342719T1 (de) 2006-11-15
MXPA05005462A (es) 2005-07-25
HK1065706A1 (en) 2005-03-04
NZ540190A (en) 2007-03-30
ES2273062T3 (es) 2007-05-01
KR20050086886A (ko) 2005-08-30
ZA200503750B (en) 2006-11-29
NO20052959L (no) 2005-06-16
BR0316947A (pt) 2005-10-18
US7632859B2 (en) 2009-12-15
US20040116537A1 (en) 2004-06-17
PL219696B1 (pl) 2015-06-30
PT1426049E (pt) 2005-09-30
CA2505040A1 (en) 2004-06-17
CY1106256T1 (el) 2011-06-08
RU2339372C2 (ru) 2008-11-27
CA2505040C (en) 2012-10-16
DK1567146T3 (da) 2007-02-19
CN100333723C (zh) 2007-08-29
WO2004050083A1 (en) 2004-06-17
PT1567146E (pt) 2007-01-31
ATE295726T1 (de) 2005-06-15
DE60204229T2 (de) 2006-02-02
DE60309203T2 (de) 2007-08-23
DE60204229D1 (de) 2005-06-23

Similar Documents

Publication Publication Date Title
DK1426049T3 (da) Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
NO20026196D0 (no) Kinazolinditosylatsalt forbindelser
CY1114645T1 (el) Συνθεση αλατος φεντανυλης για ρινικη χορηγηση
DE602004006536D1 (de) Bekämpfng von parasiten in tieren durch anwendung von imidazoä1,2-büpyridazinderivaten
BRPI0519178A2 (pt) composiÇço de cuidado oral, e, mÉtodo de prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
BRPI0413785A (pt) composto, composição, e, método de tratamento de distúrbio hiperproliferativo
BR0308813A (pt) Tratamento de tuberculose usando derivados de pleuromutilina
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
DK1706128T3 (da) Farmaceutiske sammensætninger og fremgangsmåder til insulin-behandling
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
ATE393917T1 (de) Identifikation von therapeutische verbindungen.
DE60144383D1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
BRPI0411382A (pt) derivados de 2-aminobenzoil
BR0308753A (pt) Método para produzir pseudo-ilhotas
RU2003135781A (ru) Способ лечения ревматоидного артрита
RU2004113429A (ru) Способ лечения зрительного утомления у пользователей компьютерами
ITPG20020109A1 (it) Vaschetta ionoforesi per il trattamento dell'iperidrosi palmare e plantare.
UA4215U (uk) Спосіб лікування тунельних нейропатій нижніх кінцівок
UA2858U (uk) Спосіб лікування наркоманії
UA3848U (uk) Спосіб активації процесів метаболізму у високопродуктивних корів